$AUTL

Autolus Therapeutics plc (Nasdaq: AUTL) said it secured a senior secured notes facility up to $250 million with Perceptive Advisors, including $75 million upfront, $25 million at Autolus’ option, and up to $150 million tied to revenue milestones. Autolus issued warrants for up to 3.5 million ADS. The company expects funding into Q2 2028.

Biotech gainers on Monday included Universe Pharmaceuticals (UPC), which reported six-month ended March 31, 2026 revenue of $9.03 million and net loss of $1.55 million, and shares rose about 99% to $6.48. Cumberland Pharma (CPIX) rose over 38% ahead of Q2 results after a $100 million branded portfolio sale. Autolus (AUTL) gained about 22% on preliminary Q2 Aucatzyl net product revenue of about $45 million. Other movers included Pulmonx (LUNG), SL Science (SLBT), CAMP4 (CAMP), and Beyond Air (XAI

Autolus Therapeutics plc (AUTL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 3 d156965dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 Execution Version CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. THE OMISSIONS HAVE BEEN INDICA

Autolus Therapeutics plc (NASDAQ:AUTL) said its board compensation committee granted inducement awards to 13 new employees under its 2025 Inducement Plan. Awards include options for 25,420 ADS and 87,530 RSUs, with June 24, 2026 grant dates. Options exercise at $1.66 and vest over four years. H.C. Wainwright reiterated Buy and raised its price target to $10 from $9.

Autolus Therapeutics plc (AUTL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. autl-20260629 0001730463 FALSE 0001730463 2026-06-29 2026-06-29 0001730463 sic:Z8880 2026-06-29 2026-06-29 0001730463 us-gaap:CommonClassAMember 2026-06-29 2026-06-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Secti

Autolus Therapeutics (AUTL) reported a strong increase in AUCATZYL net product revenue to $26.2 million in Q1 2026, up from $9.0 million a year prior, achieving its first positive gross margin for its acute lymphoblastic leukemia business. Despite this, the company still posted a net loss of $71.6 million. Autolus is implementing a cost reduction plan, including a 13% workforce reduction, aiming for $15 million in annualized operating expense savings from 2027 and reconfirming 2026 AUCATZYL revenue guidance of $120–$135 million, with cash reserves projected to fund operations into Q4 2027.

Autolus Therapeutics PLC is projected to report a loss of 26 cents per share, according to a preview of their upcoming earnings. This forecast comes from Refinitiv, indicating analyst expectations for the company's financial performance.

Autolus Therapeutics (AUTL) announced a strategic plan on April 29, 2026, to streamline operations, including a 13% workforce reduction by Q3 2026, which is expected to incur $8 million in charges but yield $15 million in annual savings from 2027. The company reaffirmed its 2026 revenue guidance for AUCATZYL at $120-$135 million, anticipates a positive gross margin, and projects its cash reserves will fund operations into late 2027. Despite the headcount reductions, Autolus is focused on long-term value creation and the progression of its clinical programs.

Autolus Therapeutics (NASDAQ: AUTL) announced a restructuring plan to improve operational efficiency and reduce operating expenses, which includes a 13% reduction in its workforce. The company expects to incur about $8 million in restructuring charges, mainly severance, with the majority recognized in the first half of 2026, and anticipates annual operating expense savings of approximately $15 million starting in 2027. Autolus reaffirmed its full-year 2026 AUCATZYL net product revenue guidance of $120 million to $135 million and expects its cash and equivalents to fund operations into the fourth quarter of 2027.

Mizuho analyst Mara Goldstein reiterated an Outperform rating and $12.00 price target for Autolus Therapeutics plc (NASDAQ: AUTL), following the company's Q4 2025 earnings call. The analyst noted that Aucatzyl revenue was in line with expectations and guidance for 2026 remains unchanged. Key discussion points included Aucatzyl's launch and manufacturing, as well as upcoming Phase 1 readouts which could clarify the path forward for obe-cel in areas beyond B-ALL.